151 related articles for article (PubMed ID: 23708665)
1. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract][Full Text] [Related]
2. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
3. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
Tran TH; Utama FE; Lin J; Yang N; Sjolund AB; Ryder A; Johnson KJ; Neilson LM; Liu C; Brill KL; Rosenberg AL; Witkiewicz AK; Rui H
Cancer Res; 2010 Feb; 70(4):1711-21. PubMed ID: 20124477
[TBL] [Abstract][Full Text] [Related]
4. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
5. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.
Liu R; Zhou Z; Zhao D; Chen C
Mol Endocrinol; 2011 Jul; 25(7):1137-44. PubMed ID: 21566082
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
[TBL] [Abstract][Full Text] [Related]
7. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
8. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
[TBL] [Abstract][Full Text] [Related]
9. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
[TBL] [Abstract][Full Text] [Related]
10. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.
Yang N; Liu C; Peck AR; Girondo MA; Yanac AF; Tran TH; Utama FE; Tanaka T; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Rui H
Breast Cancer Res; 2013; 15(5):R73. PubMed ID: 24004716
[TBL] [Abstract][Full Text] [Related]
11. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.
Knox AJ; Scaling AL; Pinto MP; Bliesner BS; Haughian JM; Abdel-Hafiz HA; Horwitz KB
Breast Cancer Res; 2014 Aug; 16(4):418. PubMed ID: 25116921
[TBL] [Abstract][Full Text] [Related]
12. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.
Walker SR; Nelson EA; Yeh JE; Pinello L; Yuan GC; Frank DA
Mol Cell Biol; 2013 Aug; 33(15):2879-90. PubMed ID: 23716595
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 5 alters β-catenin dynamics in breast cancer cells.
McGinn O; Ward AV; Fettig LM; Riley D; Ivie J; Paul KV; Kabos P; Finlay-Schultz J; Sartorius CA
Oncogene; 2020 Mar; 39(12):2478-2492. PubMed ID: 31988452
[TBL] [Abstract][Full Text] [Related]
14. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
[TBL] [Abstract][Full Text] [Related]
15. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.
Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
[TBL] [Abstract][Full Text] [Related]
16. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
17. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
19. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
[TBL] [Abstract][Full Text] [Related]
20. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Barcus CE; O'Leary KA; Brockman JL; Rugowski DE; Liu Y; Garcia N; Yu M; Keely PJ; Eliceiri KW; Schuler LA
Breast Cancer Res; 2017 Jan; 19(1):9. PubMed ID: 28103936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
